New Delhi: The first phase of clinical trial on humans of ‘Kovaxin’, India’s first indigenously developed vaccine for the prevention of Novel Corona Virus (COVID 19), started at AIIMS here on Friday and one between 30 and 40 years old The person was given the first injection. More than 3,500 people have registered themselves for testing at AIIMS since last Saturday, of which at least 22 are under screening. This information was given by Dr. Sanjay Rai, Professor and Chief Studies, Community Medicine Center at AIIMS.
First phase of human trial of Covaxine begins, dose given to first person in AIIMS
Dr. Rai told, “The first person resident of Delhi was examined two days ago and all his health parameters were found to be at a normal level. He is not suffering from any other disease. The first dose of 0.5 ml from the injection was given to him at 1.30 pm. Given around. No side effects have been seen yet. He was under observation for two hours and will be monitored for the next seven days. ”
They will be vaccinated on Saturday after screening reports of some more participants involved in the clinical trial. The Indian Council of Medical Research (ICMR) has selected 12 institutes, including AIIMS, for clinical trials in the first and second phases of ‘Covexin’. The first phase will test 375 people and maximum of these will be from 100 AIIMS.
Cipla is ready to launch ‘Favipiravir’ drug for treatment of Covid-19 patients
According to Dr. Rai, in the second phase, a total of about 750 people from all 12 institutions will be involved. In the first phase, the vaccine will be tested on healthy people between 18 and 55 years who do not have any other disease. According to AIIMS director Dr. Randeep Guleria, in the second phase, this test will be done on 750 people between the ages of 12 and 65 years.
So far, the first phase of human trials has started in AIIMS Patna and some other institutes. Guleria said, “In the first phase we see the safety of the vaccine which is the most important and the dose range is also measured.”
Leave a Reply